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a b s t r a c t
Objective: To assess the association of the polymorphisms of the interleukin-18 (IL-18) gene 
with rheumatoid arthritis (RA) and with risk factors for cardiovascular diseases (CVD). 
Methods: This sample comprised 97 patients with RA and 151 healthy controls. In the pa-
tients, risk factors for CVD were analyzed, such as cholesterol levels, arterial hypertension, 
smoking habit, C-reactive protein (CRP) level, and rheumatoid factor. DNA was extracted 
and the single nucleotide polymorphisms (SNP) at the -607C/A and -137G/C positions of 
the IL-18 gene were assessed in both groups. The Hardy-Weinberg equilibrium (HWE) was 
calculated and the odds ratio (OR) test performed, considering a 95% CI and P < 0.05. 
Results: The frequencies of the -607A allele in patients with RA and in controls were 0.443 
and 0.424, respectively, and of the -137C allele, 0.304 and 0.291, respectively. The genotype 
frequencies were in HWE, except for controls in the -137 locus (P = 0.006). Association of 
the polymorphisms of the IL-18 gene was found with neither RA nor risk factors for CVD, 
including cholesterol level and CRP (P > 0.05). In addition, more smokers were found among 
patients with RA as compared with controls (OR = 1.691; P = 0.088), and the CRP levels were 
slightly higher in patients who smoked than in patients who did not (OR = 2.673; P = 0.061). 
Conclusions: In this sample of patients with RA in the South of Brazil, association of the 
polymorphisms of the IL-18 gene was observed with neither RA nor risk factors for CVD.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Ausência de associação entre os polimorfi smos do gene interleucina-18 
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Objetivo: Analisar a associação dos polimorfi smos do gene interleucina-18 (IL-18) com 
artrite reumatoide (AR) e com fatores de risco de doenças cardiovasculares (DCV). 
Métodos: A amostra foi constituída por 97 pacientes com AR e 151 controles saudáveis. Nos 
primeiros, foram analisados fatores de risco de DCV, tais como níveis do colesterol, hi-
pertensão arterial, tabagismo e fator reumatoide, bem como o nível da proteína C-reativa 
(CRP). O DNA foi extraído e foram analisados os polimorfi smos de nucleotídeo único (SNP) 
nas posições -607C/A e -137G/C do gene IL-18 em ambos os grupos. O equilíbrio de Hardy-
-Weinberg (EHW) e o odds ratio (OR) foram realizados, considerando IC 95% e P < 0,05. 
Resultados: As frequências do alelo -607A nos pacientes com AR e nos controles foram de 
0,443 e 0,424 e do alelo -137C foram de 0,304 e 0,291, respectivamente. As frequências do 
genótipo estavam em EHW, exceto em controles no locus -137 (P = 0,006). Não foi encon-
trada associação dos polimorfi smos do gene IL-18 com AR, nem com fatores de risco de 
DCV, incluindo o nível do colesterol e de CRP (P > 0,05). Além disso, observaram-se mais 
indivíduos fumantes entre pacientes com AR em comparação aos controles (OR = 1,691; 
P = 0,088), e os níveis de CRP eram ligeiramente mais elevados em pacientes fumantes 
quando comparados aos de pacientes não fumantes (OR = 2,673; P = 0,061). 
Conclusões: Ao analisar uma amostra de pacientes com AR no sul do Brasil, não foi encon-
trada associação dos polimorfi smos do gene IL-18 com AR, nem com os fatores de risco 
de DCV.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease 
characterized by chronic infl ammation, leading to joint de-
struction and systemic complications which increase mor-
bidity and mortality.1,2 This disease affects 0.5%–1% of the 
general population worldwide, with a higher incidence in 
women than in men.3 Although the incidence and clinical 
manifestations of RA have been shown to vary in many dif-
ferent geographical regions, in Latin America, especially in 
Brazil, this information is scarce.4,5 Therefore, it is very im-
portant to enlighten RA pathogenesis in heterogeneous pop-
ulation such as in Brazil.
The RA has a complex and unclear etiology, but in ge-
netically susceptible individuals, specifi c environmental 
factors can potentially activate pathogenic immune reac-
tions, including autoantibody formation and autoreactivity 
response.1-3,6 The onset of RA can be indicated by the devel-
opment of antibodies against citrullinated protein antigens 
(ACPA) and rheumatoid factor (RF) related to the self-toler-
ance loss.7 Recently, it has been recognized two RA subsets 
based on presence or absence of ACPA. Patients with ACPA 
positive have more extra-articular manifestations, smoking 
habit, and worse prognosis.2 The main cause of mortality in 
RA patients is cardiovascular diseases (CVD). Once the risk of 
CVD in RA patients is 50% higher when compared with the 
general population, it is believed that other risk factors are 
present in RA disease.8,9 Thus, the pathogenesis of accelerat-
ed cardiovascular damage is caused by traditional cardiovas-
cular risk factors in combination to disease-related infl am-
matory and autoimmune mechanisms.10,11
Infl ammation has an important role in atherosclerotic 
lesion and RA patients have a higher prevalence of athero-
sclerosis.12 In immune-mediated diseases such as RA, the 
accelerated and early atherosclerotic vascular damage may 
partially be explained by humoral and cellular autoimmune 
response against antigens expressed on the endothelium.8,13 
Cytokines are also implicated in many immune processes 
associated with the pathogenesis of RA, especially in main-
taining the active chronic infl ammatory response. Because 
cytokines are involved in immune-regulatory and tissue-
destructive events, it is likely that they would infl uence the 
severity of RA manifestations.7 Interleukin-18 (IL-18), a pro-
infl ammatory cytokine produced in RA by several synovium 
cells such as macrophages, chondrocytes and osteoblasts, 
induces signaling pathways common to other IL-1 family 
members, such as activation of nuclear factor-κB (NF-κB) and 
interferon-γ expression.7,14–16
Administration of IL-18 to mice caused development of 
erosive, infl ammatory arthritis, suggesting that this cytokine 
can play a pro-infl ammatory role in vivo.14 Furthermore, IL-18 
mRNA and its protein were detected in RA synovial tissues in 
higher levels than in osteoarthritic controls.14 The structure, 
levels and regulation of IL-18 can be due to genetic differ-
ences on IL-18 gene expression.16
The chronic infl ammatory condition seen in RA increase 
the levels and expression of C-reactive protein (CRP), tumor 
necrosis factor alpha (TNFα), interleukins-1, -6, and also -18, 
which are relevant as CVD risk factors.11,13,19 IL-18 is consid-
ered pro-atherogenic, presumably as a mediator of vascular 
infl ammation itself, leading to augmentation and vulner-
ability of atherosclerotic plaque and fi nally, to its rupture.18 
Human adipocytes are also capable of producing IL-18, con-
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tributing to systemic IL-18 concentrations and development 
of the increased risk of diabetes and CVD that are associated 
with obesity and insulin resistance states.19
Plasma IL-18 concentration has shown to be increased 
in post myocardial infarction patients and was associated 
with coronary atherosclerosis.20 Indeed, variations in the IL-
18 gene were associated with raised IL-18 serum concentra-
tions and higher cardiovascular mortality among coronary 
artery disease (CAD) patients.21 Other studies showed that 
IL-18 gene polymorphisms are involved in the development 
of ischemic stroke,22 myocardial infarction (MI),23 and higher 
cardiovascular mortality risk.24 Moreover, IL-18 serum levels 
were associated with traditional risk factors such as LDL- and 
HDL-cholesterol abnormal values, obesity, insulin resistance 
and cell dysfunction.20
Even though the endogenous production of IL-18 is affect-
ed by multiple factors, individual differences could also be 
determined by genetic polymorphisms, potentially affecting 
the balance between Th1 and Th2 cytokine responses. This 
mechanism could be responsible for an increased resistance 
to microbial infections, but also for a higher susceptibility to 
autoimmune disorders in individuals carrying more active 
IL-18 alleles.15
The IL-18 gene is regulated by its promoter region poly-
morphisms, which variability could lead to differences in 
transcription factor binding. Two single nucleotide poly-
morphisms (SNPs) in the promoter region at -607C/A and 
-137G/C position have been studied, and those changes dis-
rupts a potential binding site of the cAMP-responsive ele-
ment binding (CREB) protein and the H4TF-1 nuclear factor, 
respectively.15,25
In RA patients, the higher frequency of -607A allele and/
or higher frequency of -137C allele are related to defi ciency in 
gene transcription; that would be benefi cial for the individ-
ual, protecting against the development of RA. Accordingly, 
one study demonstrates that the -607AA genotype is associ-
ated with lower prevalence of RA in a Chinese population.25
On the other hand, the homozygous for C at position -607 
and G at position -137 promote higher levels of IL-18 mRNA 
compared to the other genotypes, and the resulting elevated 
levels of the pro-infl ammatory IL-18 protein mediate many 
acute and chronic infl ammatory processes.15,25
The aim of this study was to analyze the infl uence of the 
IL-18 polymorphisms on RA pathogenesis, as well as in CVD 
risk factors (dyslipidemia, blood pressure, smoking).
Methods
Ninety seven RA patients diagnosed according to 1987 ACR 
classifi cation criteria, from the outpatient clinic of the Rheu-
matology Division at the University Hospital of the Federal 
University of Santa Catarina, Florianópolis, Brazil, were en-
rolled. Control group was composed by 151 healthy volun-
teers without personal or family history of autoimmune dis-
eases. The study was approved by the local Ethics Committee 
(CEP/UFSC – case number 172/06). All participants gave their 
written informed consent. Familial and epidemiologic data 
were collected using structured questionnaires. Clinical data 
were obtained from medical records.
As traditional CVD risk factors, we considered: high to-
tal (>  200  mg/dL) and LDL (>  100  mg/dL) cholesterol levels, 
systemic arterial hypertension (systolic arterial pressure (AP) 
≥ 140 mmHg and/or dyastolic AP ≥ 90 mmHg), current smok-
ing habit, RF positivity (> 20 IU/mL), and levels of CRP above 
the reference value (> 5mg/L).
Peripheral blood samples were collected for DNA extrac-
tion.26 The SNP -607C/A (rs1946518) of IL-18 gene was detected 
by the polymerase chain reaction restriction fragment length 
polymorphism (PCR-RFLP) technique, amplifying a 301 base 
pair (bp) segment covering the polymorphic site by using the 
primers sequences on Table 1.27 To detect the polymorphism, 
the PCR products were followed by MseI restriction enzyme 
(BioLabs Inc., New England) digestion, at 37°C for 12 hours, 
then subjected to electrophoresis in a 3% agarose gel and 
stained with ethidium bromide (1%). The digested PCR prod-
ucts were identifi ed as CC homozygous individuals when cut 
into 199 and 73bp fragments, and as AA homozygous indi-
viduals when cut into 101, 98 and 73 bp fragments. Thus, the 
CA heterozygous individuals were identifi ed when showing 
the expected fragments: 199, 101, 98 and 73 bp (Fig. 1a). 
The SNP -137G/C (rs187238) of the same gene was detect-
ed by sequence specifi c PCR (PCR-SSP) method, according to 
Takada et al. (2002).27 In this method were used a common 
reverse primer (R) and two sequence-specifi c forwards prim-
ers, specifi c F1 for C allele and specifi c F2 for G allele, am-
plifying a product of 261 bp (Table 1). As an internal positive 
amplifi cation control, a control forward primer (F) was used 
to amplify a 446 bp fragment which covers the polymorphic 
site (Table 1) (Fig. 1b). For confi rmation of typing, we used 
negative and positive controls for each genotype in all ex-
periments in both SNP detection methods.
The frequencies of alleles and genotypes in RA patients 
and controls of both SNPs -607 and -137 was performed 
by direct counting. To verify the genotype distribution, the 
Hardy-Weinberg Equilibrium (HWE) test was calculated us-
ing GENEPOP software.28 Since both SNPs are located in the 
same gene, we have verifi ed if they were inherited together 
due to linkage disequilibrium (LD) using GENEPOP software. 
Once both SNPs are linked, they can be considered as one 
haplotype, and frequency of its combination was calculated 
by PHASE software.29
The odds ratio (OR) with 95% confi dence interval was ob-
tained for association analysis30 of the polymorphisms (al-
leles, genotypes and haplotypes). The analysis was performed 
Table 1 – Primers sequences used to amplify the -607 
and -137 single polymorphisms nucleotide (SNP) in 
promoter site of interleukin (IL)-18 gene by polymerase 
chain reaction (PCR).
Position Primers sequences*
-607 F: 5-CTTTGCTATCATTCCAGGAA-3
R: 5-TAACCTCATTCAGGACTTCC-3
-137 control F: 5-CCAATAGGACTGATTATTCCGCA-3
control R: 5-AGGAGGGCAAAATGCACTGG-3
Allele C specifi c F1: 5-CCCCAACTTTTACGGAAGAAAAG-3
Allele G specifi c F2: 5-CCCCAACTTTTACGGAAGAAAAC-3
*F, forward primer; R, reverse primer. 
G and C denote alleles.
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separately for clinical and epidemiological data as well as for 
RA susceptibility and further confi rmed using the HDS Epi-
Max Calculator.31 The -607A and -137G alleles were considered 
as risk alleles to RA susceptibility. A P value below 0.05 was 
considered signifi cant.
Results
Women were 88.66% of the RA patients and 96.40% of the con-
trols (P > 0.05). Mean age was 54.63 (± 12.48) in patients and 
48.00 (± 15.56) years old in controls (P > 0.05). Although in RA 
and controls the predominant ethnicity was Euro-Brazilian, 
frequency of Afro-Brazilians and Amerindian-Brazilians was 
higher in RA patients than in controls (P = 0.027) (Table 2).
The allele, genotype and haplotypes frequencies of IL-18 
gene polymorphisms were estimated in case and controls. 
The allele frequencies were showed in Table 3. The genotype 
frequencies distribution for both SNPs were in HWE in RA pa-
tients and controls, except for the genotype frequencies for 
-137 SNP in controls (P = 0.006) (Table 4). Furthermore, because 
we found that the polymorphisms -607 and -137 were in link-
age disequilibrium in RA patients and controls (P  < 0.001), 
both SNPs were analyzed as haplotypes (Table 5). We showed 
that the allele, genotype and haplotype frequencies of IL-18 
gene were similar in RA patients and controls, and the IL-18 
polymorphisms were not associated with the development of 
RA (P > 0.05).
Among the prevalence of CVD risk factors in RA patients, it 
was observed the presence of hypercholesterolemia (54.95%), 
arterial hypertension (56.99%), smoking habit (41.76%), positive 
RF (66.27%), and high CRP levels (52.38%) (Table 2). High cho-
lesterol levels and arterial hypertension were not associated 
with IL-18 gene polymorphisms. Also, we observed that smok-
ing habit in RA patients have a tendency to be associated with 
levels of positive RF (OR = 2.199; 0.739–6.677 95 CI%; P = 0.182), 
and CRP high levels (OR = 2.673; 0.961–7.546 95% CI; P = 0.061). 
The frequency of smokers was higher among RA patients than 
in controls (OR = 1.691; 0.930–3.079 95% CI; P = 0.088), however 
not statistically signifi cant. Furthermore, neither RF nor smok-
ing was associated with -607 or -137 polymorphisms. 
Discussion
This is an important study that analyses for the fi rst time in 
a Brazilian population the genetic features of the pro-infl am-
matory cytokine IL-18, and its role in RA. This cytokine can 
be involved in the characteristic infl ammatory condition that 
causes so many injuries in RA patients.
The genotype frequencies of both -607 and -137 SNPs found 
in the present study resemble to other case-control studies 
including Caucasian RA patients, such as Polish,32 and Span-
ish.33 On the other hand, the genotype frequencies found in 
Asian studies differ from ours.25,34 Thus, the similarity to the 
European population regarding genotype frequencies could 
be explained by the high prevalence of Euro-descendants in 
our sample, since many immigrants from Europe were settled 
in Southern Brazil.35
A Chinese study found that the AA genotype of -607 SNP 
confers protection against RA development.25 However, this 
study showed no association between both -607 and -137 
SNPs of IL-18 gene and susceptibility for RA development. In 
the same way, a recent meta-analysis on autoimmune dis-
eases36 concluded that these polymorphisms were not related 
to RA development, similar to other studies done in Poland,32 
Spain,33 and China.34 The latter study also showed that -607 
SNP did not change IL-18 serum levels.34
Fig. 1 – Genotyping for the IL-18 position -607 (a) and -137 (b) polymorphisms. (a) Genotyping SNP -607 C/A locus in IL-18 
gene by PCR-RFLP technique, whose PCR products were followed by MseI (Biolabs, New England) digestion at 37°C for 12 
hours, then subjected to electrophoresis 3% agarose gel and stained with ethidium bromide (1%).27 (b) Genotyping SNP -137 
G/C locus in IL-18 gene by PCR-SSP technique, whose PCR products are allele specifi c, subjected to electrophoresis 1.5% 
agarose gel and stained with ethidium bromide (1%).27 In the picture, each lane represents an individual. In (1) the PCR 
products were amplifi ed with specifi c primer to G allele (arrow). In (2) the PCR products were amplifi ed with specifi c primer 
to C allele (arrowhead). The fragment that was amplifi ed by specifi c primers had 261 bp, while an intern control is present 
in both assays and amplifi ed a fragment with 446 bp. Thus, if both bands are present in the gel it means that the specifi c 
allele is present (e.g. lane 2 represents the genotype GC). 
L, 50bp ladder; 1, PCR product (301bp) without digestion; samples 2 and 4 were genotype as CA (199bp. 101bp. 98bp and 73bp); 
sample 3 was genotyped as AA (101bp. 98bp and 73bp) and sample 5 was considered as CC genotype (199 bp and 73 bp).
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Although RA is a disease of complex etiology, it is believed 
to be caused by the combination of genetic susceptibility and 
several environmental factors such as infections and lifestyle 
characteristics, the exact contribution of each of these factors 
for RA development in distinct populations are not well un-
derstood and need further investigation.3,37
We demonstrated that the IL-18 SNPs were in linkage dis-
equilibrium in RA patients, as it was ever previously shown 
by other studies.25,32,33 Also, we found no association of hap-
lotypes with RA susceptibility, in agreement to results from 
Spanish34 and Chinese studies.25 Nevertheless, a study from 
Poland found a signifi cant decreased number of subjects 
with AC/AC and AG/AG diplotypes among RA patients as 
compared with controls, suggesting these diplotypes are re-
lated to RA development.32 The polymorphisms in the IL-18 
promoter gene affect its activity, but this effect depends on 
Table 2 – Clinical and epidemiological characterization of rheumatoid arthritis patients and controls from Southern 
Brazil.
Patients, n (%) Total, n * Controls, n (%) Total, n *
Epidemiological data
Female 86 (88.65) 97 146 (96.40) 151
Mean age 54.63 (± 12.48) 97 48.00 (± 15.56) 151
Euro-Brazilian 69 (75.82) 91 121 (88.32) 137
Afro-Brazilian 20 (21.98) 91 15 (10.94) 137
Amerindian-Brazilian 2 (2.20) 91 1 (7.29) 137
Smoking habit 38 (41.76) 91 39 (29.77) 131
Clinical data
Hypercholesterolemia 50 (54.95) 91 MD  
Arterial hypertension 53 (56.99) 93 MD  
Positive RF 55 (66.27) 83 MD  
High CRP levels 44 (52.38) 84 MD  
MD, missing data.
* The n value differs because of data availability.
Table 4 – Genotypes frequencies of promoter IL-18 polymorphisms (-607C/A and -137G/C) in rheumatoid arthritis 
patients and controls.
RA patients n = 97 (%) Controls n = 151 (%) OR (95% CI) P
-607 Genotypes
CC
CA
AA
(CA+AA) versus CC
31 (32)
46 (47)
20 (21)
—
 
48 (32)
78 (52)
25 (16)
—
 
1.0 (Ref.)
0.914 (0.497-1.681)
1.164 (0.522-2.593)
0.947 (0.550-1.729)
 
—
0.86
0.83
1.00
HWE χ2 = 0.149
—
—
χ2 = 0.502
—
—
0.83
0.33
-137 Genotypes
GG
GC
CC
(GC+CC) versus GG
 
45 (46)
45 (46)
7 (8)
—
 
70 (46)
74 (49)
7 (5)
—
 
1.0 (Ref.)
0.946 (0.540-1.658)
1.556 (0.452-5.365)
0.999 (0.580-1.720)
 
—
0.94
0.62
1.00
HWE χ2 = 0.599
—
—
χ2 = 5.264
—
—
0.34
0.006
IL-18,interleukin-18; RA, rheumatoid arthritis; OR, odds ratio; χ2, chi-square value; CI, confi dence interval. 
P < 0.05 was considered signifi cant. 
The -607CC and -137GG genotypes were considered as reference (OR = 1.0).
Table 3 – Allele frequencies of promoter IL-18 polymorphisms (-607C/A and -137G/C) in rheumatoid arthritis patients 
and controls.
RA patients, n = 97(%) Controls, n = 151(%) OR (95% CI) P
SNP-607
Allele A 43 (44.3) 64 (42.4) 1.064 (0.732–1.547) 0.80
SNP-137
Allele C 30 (30.4) 44 (29.1) 1.063 (0.703–1.606) 0.84
IL-18,interleukin-18; RA, rheumatoid arthritis; OR, odds ratio; CI, confi dence interval.
P < 0.05 was considered signifi cant.
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cell types and local cytokine environment. Thus, the interac-
tion between genotype and cellular environment remains to 
be evaluated.15
Although dyslipidemia is a controversial factor of CVD in 
RA, studies showed that low levels of HDL-cholesterol are com-
mon and could contribute for increased CV morbidity in these 
patients.8,17,38,39 Dyslipidemia has been associated with high lev-
els of IL-18.20 However, our study showed that high levels of to-
tal cholesterol were not associated with the presence of the IL-
18 SNPs analyzed, which was found by other studies as well.24,40
Arterial hypertension is common among RA patients, but 
the cause of this increased prevalence compared with con-
trols is unclear. There are multiple factors that infl uence blood 
pressure, such as obesity, physical inactivity, specifi c genetic 
polymorphisms, and some antirheumatic medications.8,37 Ar-
terial hypertension is associated with increased IL-18 serum 
levels,20 and the expression of mRNA of this cytokine in ath-
erosclerotic tissue samples was augmented when the -137GC 
polymorphisms and arterial hypertension were both present.41 
Furthermore, a study about metabolic risk factors for CVD 
found that -137GC genotype confers increased risk of arterial 
hypertension development to African women when compared 
with -137GG subjects.41 In our study, however, arterial hyper-
tension was not associated with IL-18 polymorphisms, as also 
demonstrated by Szeto et al.24
Smoking is a known risk factor for development of RA, and 
smokers with RA appear to have higher RF titers and worse 
prognosis in terms of disability, radiographic damage, and 
treatment response.38 We found no association between smok-
ing habit and the IL-18 polymorphisms, nor between smoking 
habit and RF in RA patients (OR = 2.2; P > 0.05), which differs 
from data of a recent meta-analysis.38 In the same way, the 
presence of RF was not associated with the polymorphisms of 
IL-18 gene, as showed by other studies in RA.15,33 High levels of 
CRP were more frequent in RA patients who smoke, but this as-
sociation was not statistically signifi cant (OR = 2.67; P = 0.061). 
CRP levels were not associated with IL-18 gene polymorphisms, 
similarly to the results of another study.24
Although other studies have demonstrated that expression 
of IL-18 gene is higher in RA patients and that this cytokine 
might be relevant in the pathogenesis of the disease, we found 
that the polymorphisms -607 and -137 of IL-18 gene do not play 
a major role in RA susceptibility in our population. In addition, 
these polymorphisms are not associated with CVD risk factors 
in our RA patients.
IL-18 exhibits pleiotropic activities in RA, with a wide va-
riety of effects that are infl uenced by the overall cytokine 
network. Future studies considering novel genetic markers 
within IL-18 or other genes involved in the cytokine network 
should be performed to evaluate their relevance in the con-
text of RA and other infl ammatory diseases.
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